Rapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary.
Rapport priced 9,615,385 shares at $26.00 the day after reporting Phase 2a epilepsy data for RAP-219, with net proceeds of about $234.7 million. The data came from 30 treated patients and were tested against fixed null rates, not a placebo group.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $63.6 million, plus short-term investments of $372.5 million, $436.1 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Rapport Therapeutics
Has Rapport Therapeutics raised money recently?
Our latest story on this, dated Oct 27, 2026: "Rapport Therapeutics launches stock offering and convertible notes due 2032". The story links the filing or release it is based on. Read the story.
Has Rapport Therapeutics sold convertible notes?
Our latest story on this, dated Oct 27, 2026: "Rapport Therapeutics launches stock offering and convertible notes due 2032". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Rapport Therapeutics?
Rapport Therapeutics, Inc. trades under the ticker RAPP on NASDAQ.
Where is Rapport Therapeutics listed?
Rapport Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Rapport Therapeutics?
The SEC Central Index Key (CIK) for Rapport Therapeutics, Inc. is 2012593. Its filings are on SEC EDGAR.
How many shares does Rapport Therapeutics have outstanding?
47,978,286 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Rapport Therapeutics listed under?
Our directory records Rapport Therapeutics, Inc. under United States.
What does Rapport Therapeutics do?
Our directory classifies Rapport Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Rapport Therapeutics?
The ISIN recorded for Rapport Therapeutics, Inc. is US75383L1026.
Does aibio.space cover Rapport Therapeutics?
aibio.space lists Rapport Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Rapport Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Rapport Therapeutics profitable?
Rapport Therapeutics, Inc. reported a net loss of $111.5 million for the fiscal year ended Dec 31, 2025, and used $87.5 million of cash in operations, per its annual report to the SEC.
How much does Rapport Therapeutics spend on research and development?
$94.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Rapport Therapeutics have?
$436.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Rapport Therapeutics (RAPP) stock news?
Our latest story on Rapport Therapeutics, dated Oct 27, 2026: "Rapport Therapeutics launches stock offering and convertible notes due 2032". Rapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary. Source.
Investor discussion: Rapport Therapeutics
Members talk about Rapport Therapeutics (RAPP). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Rapport Therapeutics, newest first. Each line links the filing it comes from.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:RAPP on TradingView.
SEC filings and registration
SEC name
Rapport Therapeutics, Inc.
CIK
2012593
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
RAPP (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
99 HIGH STREET, BOSTON, MA, 02110
Phone
857-321-8020
Shares outstanding
47,978,286 as of 2026-08-03 (10-Q filed 2026-08-05)
Former names
Rapport Therapeutics, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Rapport Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RAPP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio